RE:RE:PD-(L)1 checkpoint inhibitors to reach $58 Billion by 2025Should read: .. " This FDA approval will establish pelareorep as a monotherapy I/O agent that can be combined with multiple other large and small molecule immunotherapy agents, such as PD-L1 immune checkpoint inhibitors, bispecifics, ADCs, CAR-T therapy and small molecules such as CDK4/6. PARP and VEGF inhibitors."